Eli Lilly Reports Results of Tirzepatide in P-III SURPASS-3 MRI Sub-Study for the Treatment of Type 2 Diabetes
Shots:
- The P-III SURPASS-3 MRI sub-study evaluates the effects of tirzepatide (5/10/15mg- qw) vs titrated insulin degludec on LFC- VAT and ASAT in 296 patients with T2D for 52wks.
- The study met its 1EPs & 2EPs i.e.- (-8.09% from 15.67% vs -3.38% from 16.58%) absolute reduction from baseline in LFC for 10 & 15 mg dose; relative reduction (29.78% - 47.11% vs 11.17%) & patients achieved a 30% reduction in LFC from baseline (66.9%-81.4% vs 32.12%) for 3 doses- overall safety profile was similar to well-established GLP-1 receptor agonist
- The therapy showed a reduction in the volume of VAT & ASAT @52wks. Tirzepatide is a dual GIP & GLP-1 receptor agonist
Ref: PR Newswire | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com